Tailored treatment for locally advanced rectal cancer after FOLFIRINOX
Part of Cancer, Digestive system clinical trials.
This trial studies a more customized treatment plan for people with locally advanced rectal (bowel) cancer after they receive FOLFIRINOX chemotherapy. It aims to reduce tumor spread risk and improve outcomes by tailoring the next steps based on scan details and your health status.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to sign written consent
- Have rectal adenocarcinoma confirmed by pathology (biopsy/test result)
- Have already started FOLFIRINOX chemotherapy
- Have a scan showing the cancer is in the rectum but no clear metastatic (spread) disease on CT
- MRI details must suggest a higher-risk tumor boundary (small CRM) or certain tumor extensions (T3c/T4a/T4b, with exceptions)
- Not have certain heart problems, recent blood clots, pelvic radiation, or conditions that prevent chemotherapy (like DPD deficiency)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a strong chemotherapy combination (FOLFIRINOX) followed by radiation before surgery for locally advanced rectal cancer. If you have stage 3 or high-risk stage 2 rectal cancer that has not spread, this approach may shrink the tumor and improve outcomes.
This trial compares two different chemotherapy combinations given before radiation or surgery for high-risk locally advanced rectal cancer. One arm is more intense, and the other is standard. The goal is to see which works better at shrinking the tumor and possibly avoiding surgery.
This Phase 2 trial compares a pre-surgery (neoadjuvant) treatment plan versus the standard plan for people with stage II–III rectal cancer. The goal is to see which approach works better and is safe before surgery.
This trial compares different combinations of chemotherapy drugs given before surgery to the standard approach of chemoradiation (chemotherapy plus radiation) for rectal cancer that has not spread. The goal is to see if the drug combinations are more effective at shrinking tumors and improving outcomes.
This trial tests whether combining chemotherapy (mFOLFOX6) and a short course of radiation before surgery improves outcomes for people with resectable rectal cancer. The goal is to shrink and control the cancer early and then remove it with curative surgery.
This trial compares two chemotherapy plans given before rectal cancer surgery to see which helps more people and works better for disease control. If you have locally advanced rectal cancer and have not had treatment yet, this study may be an option.
Hear when a new Rectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.